Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Eugenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | AR | P10275 | 1/20 | 0.85 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.85 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | PPARD | Q03181 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eugenol SCHEMBL27608718 | 1.00 | ALDH1A1 (0.85) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL29943804 | 1.00 | ALDH1A1 (0.85) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL27710638 | 0.98 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL22719783 | 0.93 | ALDH1A1 (0.78) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL6152218 | 0.93 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL27472855 | 0.93 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL16433004 | 0.93 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL31189370 | 0.93 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL1289317 | 0.92 | ALDH1A1 (0.93) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL28883151 | 0.92 | ALDH1A1 (0.93) | ALDH1A1ALOX5PTGS1CYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746862-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075448-A | Pharmaceutical composition with enhanced permeation | — | 2026-05-26 | — | — | CN | claimed |
| US-20260114787-A1 | Olfactory Diagnostic Compositions and Kits, and Methods of Making and Using the Same | UNIV KANSAS (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4302747-B1 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | OREAL (FR) | 2026-01-14 | — | — | EP | claimed |
| US-12514798-B2 | Use of [6]-paradol for stabilization of cosmetic compositions | SYMRISE AG (DE) | 2026-01-06 | — | — | US | claimed |
| US-12491225-B2 | Antiviral compositions and methods | RALCO NUTRITION, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-12433850-B2 | Enhanced delivery epinephrine and prodrug compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20050014827-A1 | Synergistic medicament containing flavoring agents and having an antagonistic regenerative and/or protagonist decontamination effect | SCHUR JORG P (DE) | 2005-01-20 | — | — | US | claimed |
| US-6844302-B1 | Encapsulated flavor and fragrance | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2005-01-18 | — | — | US | claimed |
| WO-2004091307-A2 | FEED ADDITIVES AGAINST DISEASSE INFECTION IN TERRESTRIAL AND AQUATIC ANIMALS | ADVANCED BIONUTRITON CORPORATION (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004062389-A1 | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND OPTIONALLY TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | HUNZA DI PISTOLESI ELVIRA & C. S.A.S. (IT) | 2004-07-29 | — | — | WO | claimed |
| US-20040076614-A1 | Symbiotic regenerative agent | SCHUR JORG P (DE) | 2004-04-22 | — | — | US | claimed |
| US-20040052922-A1 | Nutritional and therapeutical preparations having antioxidant activity | HUNZA DI PISTOLESI ELVIRA E.C. S.A.S. (IT) | 2004-03-18 | — | — | US | claimed |
| EP-1345501-A1 | NUTRITIONAL AND THERAPEUTICAL PREPARATIONS HAVING ANTIOXIDANT ACTIVITY | Hunza di Pistolesi Elvira E C. S.a.S. (IT) | 2003-09-24 | — | — | EP | claimed |
| WO-2002052955-A1 | NUTRITIONAL AND THERAPEUTICAL PREPARATIONS HAVING ANTIOXIDANT ACTIVITY | HUNZA DI PISTOLESI ELVIRA E C. S.A.S. (IT) | 2002-07-11 | — | — | WO | claimed |
| EP-0762837-B1 | PROCESS FOR IMPROVING THE SHELF LIFE OF AND/OR STABILISING PRODUCTS WHICH CAN SPOIL UNDER THE ACTION OF MICROBES | SCHUER JOERG PETER PROF (DE) | 2002-02-27 | — | — | EP | claimed |
| US-5344994-A | Process for the preparation of coniferyl aldehyde | HAARMANN & REIMER GMBH (DE) | 1994-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433850-B2 | Enhanced delivery epinephrine and prodrug compositions | ADRA2C, ADRB3, ADRA1B | ALDH1A1 542/4885ALOX5 572/4885PTGS1 1038/4885 |
| US-20260114787-A1 | Olfactory Diagnostic Compositions and Kits, and Methods of Making and Using the Same | OR51E2, OR10J3, TAS2R5 | ALDH1A1 280/4885ALOX5 35/4885PTGS1 639/4885 |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | ADRB1, ADRB2, ADRA1D | ALDH1A1 1247/4885ALOX5 785/4885PTGS1 1888/4885 |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRB1, ADRB2, ADRA1D | ALDH1A1 1324/4885ALOX5 1575/4885PTGS1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.